Literature DB >> 31721482

The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine.

Balwinder Singh1, William V Bobo2, Keith G Rasmussen1, Cynthia J Stoppel1, Jose A Rico1, Kathryn M Schak1, Joanna M Biernacka1,3, Mark A Frye1, Jennifer L Vande Voort4,1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31721482     DOI： 10.4088/JCP.19l12852

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  3 in total

1.  An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis.

Authors:  Nicolas A Nuñez; Boney Joseph; Mehak Pahwa; Ashok Seshadri; Larry J Prokop; Simon Kung; Kathryn M Schak; Jennifer L Vande Voort; Mark A Frye; Balwinder Singh
Journal:  Psychopharmacol Bull       Date:  2020-09-14

2.  Genome-wide association study and polygenic risk score analysis of esketamine treatment response.

Authors:  Qingqin S Li; Ewa Wajs; Rachel Ochs-Ross; Jaskaran Singh; Wayne C Drevets
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

3.  Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.

Authors:  Marlene P Freeman; Rebecca S Hock; George I Papakostas; Heidi Judge; Cristina Cusin; Sanjay J Mathew; Gerard Sanacora; Dan V Iosifescu; Charles DeBattista; Madhukar H Trivedi; Maurizio Fava
Journal:  J Clin Psychopharmacol       Date:  2020 May/Jun       Impact factor: 3.118
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.